Overview

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Status:
Active, not recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
In this study the investigators are comparing this standard regimen to the newly established regimen of melphalan and bortezomib.
Phase:
Phase 2
Details
Lead Sponsor:
Hackensack Meridian Health
Hackensack University Medical Center
Treatments:
Bortezomib
Melphalan